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Abstract The possible active site Cys 441 in the Cys-pocket and 
Glu 347 and Arg ~s° of the EXXR motif of the human prostacyclin 
synthase, which catalyzes the conversion of prostaglandin H2 to 
prostacyclin, were subjected to site-directed mutagenesis n order 
to understand the role of these residues in expressing the 
enzymatic activity. Five expression vectors encoding the mutant 
enzymes with a single replacement, Cys441Ala, Cys441Ser, 
Cys441His, Glu347Ala and Arg3S°Ala, as well as the wild-type 
enzyme were expressed in 293 cells. The microsomal fraction of 
the cells expressing the wild-type enzyme showed a specific 
activity of 96 nmol 6-keto-PGF1Jmin per mg protein. All of the 
mutant enzymes examined showed no detectable nzyme activity, 
although immunoblot analysis demonstrated that levels of all the 
expressed mutant enzymes were similar to that of the wild-type 
enzyme. These results indicated that the Cys 441 in the Cys- 
pocket, and Glu 347 and Arg 35° of the EXXR motif of human 
prostacyclin synthase are important for expressing the enzymatic 
activity. 
Key words." Prostacyclin synthase; Prostaglandin I2; Site- 
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1. Introduction 
Prostacyclin (prostaglandin I2: PGI2) has strong vasodila- 
tion and antithrombogenic effects and is thought o be a phys- 
iological antagonist of thromboxane A2. Thus, the balance 
between the production of PGI2 and thromboxane Az is pos- 
tulated to be important for the circulatory system, and the 
imbalance of these products causes diseases uch as myocar- 
dial infarction, stroke, and atherosclerosis [1]. PGI2 is formed 
via isomerization of PGH2 by PGI2 synthase (EC 5.3.99.4) in 
vascular endothelial cells and vascular smooth muscle cells [2]. 
We have suggested that PGI2 synthase is a hemoprotein of the 
cytochrome P450 type [3-5], and demonstrated by molecular 
cloning of PGI2 synthase cDNAs from bovine and human 
vascular endothelial cells that the enzyme belongs to a new 
family (CYPS) in the P450 superfamily [6-8]. As shown in 
Fig. 1, the cysteine residue constituting the 5th ligand of the 
heme in the Cys-pocket (the ]3-bulge region) near the helix L, 
and the glutamic acid and arginine residues of EXXR motif in 
the helix K are highly conserved among P450s [9,10]. These 
amino acid residues of P450s are also well conserved in the 
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deduced primary structure of PGI2 synthase [7,9]. On the 
other hand, many cytochrome P450s generally catalyze the 
oxidation of a variety of hydrophobic substrates, but PGI2 
synthase catalyzes the isomerization of PGH2. Therefore, it 
is of interest o study the difference between the active site 
structures of PGI2 synthase and other P450s. 
Here we performed the site-directed mutagenesis of human 
PGIe synthase. The possible active site cysteine residue Cys 441 
was replaced by alanine, serine and histidine, and Glu a47 or 
Arg 35° of the EXXR motif was mutagenized to alanine. It was 
found that all the mutations examined entirely abolished the 
enzyme activity, suggesting the importance of these residues in 
expression of the enzymatic activity of PGI2 synthase. 
2. Materials and methods 
2.1. Materials 
[1J4C]Arachidonic acid (1.85 GBq/mmol) was purchased from 
Amersham (Bucks, UK). pCMV-7 and pVA-1 [11] were obtained 
from Dr. David W. Russell (Department of Molecular Genetics, Uni- 
versity of Texas Southwestern Medical Center). 293 cells (ATCC CRL 
1573) were obtained from American Type Culture Collection (Rock- 
ville). Restriction endonuclease and other modifying enzymes were 
from Toyobo. Polymerase chain reaction (PCR) primers were synthe- 
sized on a DNA synthesizer (model 391, Perkin-Elmer). 
2.2. Expression vector and mutagenesis 
A 1.6-kb fragment of the full-length uman PGI2 synthase cDNA 
constructed by ligation of pHPGIS36 and pHPGIS135 [7] was in- 
serted into the SalI and BamHI sites of the expression vector 
pCMV-7 to generate the plasmid pCMV/PGISWT. The mutants 
were prepared by 'overlap extension' mutagenesis [12] using three- 
step PCR amplification of the cDNA for human PGI2 synthase. 
The primers for the first amplification of the cDNAs harboring the 
carboxyl terminal region of the mutant enzymes were (bases under- 
lined in the primer sequences described below indicate the changes 
introduced in the cDNA sequences): Cys 441Ala, 5'-AA- 
TCACGCGCTGGGGAGGAGTTATGCGGTCAACAGC-Y (P6, 
with a TGC to GCG substitution of the sense-strand sequence at 
nucleotide 1321-1323), and 5'-GGGATCCAGATCTTCATGGGCG- 
GATGCGGTA-Y (P48, the antisense-strand complimentary to the 3' 
region of the coding sequence); Cys441Ser, 5'-AATCACTCCCT- 
GGGGAGGAGTTATGCGGTCAACAGC-Y (P50, with a G to C 
substitution of the sense-strand sequence at nucleotide 1322) and P48; 
Cys441His, 5'-AATCACC__A_ACCTGGGGAGGAGTTATGCGGT- 
CAACAGC-Y (P49, with a TG to CA substitution of the sense- 
strand sequence at nucleotide 1321-1322) and P48; Glua47Ala, 5'- 
TTGATAGCGTGCTGAGTGCGAGCCTCAGGC-Y (P79, with an 
A to C substitution of the sense-strand of the sequence at nucleotide 
1040) and P48; Arg35°Ala, 5'-CTGAGTGAGAGCCTCGCGCTTA- 
CAGCTGC-Y (P61, with an AG to GC substitution of the sense- 
strand sequence at nucleotide 1048 1049) and P48. The PCR reactions 
were run for 25 cycles in the following cycle profile: 94°C for 1 min, 
55°C for 45 s and 72°C for 2 min. The primers for the second am- 
plification of the cDNAs covering the amino terminal region 
of the mutant enzymes were: Cys441Ala, 5'-GCTGTTGACCGCA- 
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TAACTCCTCCCCAGCGCGTGATT-3' (P7) which is complemen- 
tary to P6 and 5'-CGTCGACCCACCATGGCTTGGGCCGCG- 
CTC-3' (P57) which corresponds to the 5'-coding region of the 
cDNA; Cys 441Ser, 5'-GCTGTTGACCGCATAACTCCTCCCCA- 
GGGAGTGATT-3' (P74) which is complementary to P50 and P57; 
Cys~-lHis, 5'-GCTGTTGACCGCATAACTCCTCCCCAGGTGGT-__ 
GATT-3' (P73) which is complementary to P49 and P57; Glu347Ala, 
5'-GCCTGAGGCTCGCACTCAGCACGCTATCAA-Y (P60) which 
is complementary to P79 and P57; Arg35°Ala, 5'-GCAGCTGTA- 
AGCGCGAGGCTCTCACTCAG-3' (P62) which is complementary 
to P61 and P57. The second amplifications were performed under 
the same PCR conditions used for the 1st PCR. Finally, the full- 
length cDNAs with a mutation were prepared by the third PCR using 
the overlap extension technique [12]. The 1st and 2nd PCR products 
were purified by agarose gel electrophoresis, reannealed and reampli- 
fled using P48 and P57 as primers. The PCR was run for 10 cycles in 
the following cycle profile: 94°C for 1 min, 55°C for 45 s and 72°C for 
2 min. The products were purified, digested with XhoI and BamHI 
and introduced into the XhoI-BamHI site of the expression vector 
encoding the wild-type nzyme, pCMV/PGISWT. All the mutant vec- 
tors pCMV/PGISCys441AIa, pCMV/PGISCys 441Ser, pCMV/ 
PGISCys441His, pCMV/PGISGlua47Ala and pCMV/PGISArga5°Ala 
were completely sequenced as described in [6] to verify that no other 
mutations had been introduced by the PCR amplification. 
The constructed expression vectors were transfected into 293 cells. 
Monolayers of 293 cells were seeded (3 × 105 cells per 60 mm dish) in 
Dulbecco's modified Eagle's medium containing 10% fetal bovine ser- 
um, 100 U/ml penicillin, and 100 mg/ml streptomycin. After incuba- 
tion for 24 h, the cells were transfected with 3 gg of either an expres- 
sion vector coding for the wild-type or the mutant enzyme, or the 
control vector pCMV-7 plus 0.3 lag of pVA-1 (a plasmid encoding 
adenovirus-associated RNA1) [13] using LipofectAMINE (Gibco 
BRL). After 36 h, cells washed once with ice-cold phosphate-buffered 
saline (PBS) were harvested with PBS and stored at -80°C [14]. 
2.3. Characterization of expressed proteins 
The cells (2x 106 cells) were suspended in 1 ml of 100 mM potas- 
sium phosphate buffer (KPB), pH 7.5, 1 mM EDTA, 0.1 mM dithio- 
threitol (DTT), 0.1 mM butylated hydroxytoluene (BHT) and 44 lag/ 
ml phenylmethylsulfonyl fluoride, and sonicated 4 times at 150 W for 
30 s (Astrason, model XL2020). The homogenate was centrifuged at 
10000×g for 10 min, and the supernatant was centrifuged at 
100000×g for 1 h. Pellets were suspended in 10 mM KPB (pH 7.5) 
containing 20% (v/v) glycerol and 0.1 mM EDTA, 0.1 mM DTT, 0.1 
mM BHT (buffer A), and the protein concentration was adjusted to 
2 mg/ml with buffer A. The expressed proteins separated by SDS- 
polyacrylamide gel electrophoresis on 10% (w/v) gels were stained 
with silver nitrate (Silver stain II kit, Wako) and subjected to immu- 
noblot analysis. The proteins were transferred electrophoretically onto 
a polyvinylidene difluoride (PVDF) membrane (Immobilon, Milli- 
pore). After treatment with 5% skim milk in Tris-HCl-buffered saline 
(TBS), pH 7.4 at 24°C for 12 h, the blotted membrane was incubated 
with the polyclonal antibody against bovine PGI2 synthase [15] in 
TBS containing 3% skim milk. After rinsing with TBS containing 
0.05% Tween 20, the membrane was incubated with alkaline phospha- 
tase-conjugated anti-rabbit mmunoglobulin G in TBS containing 3% 
skim milk at 37°C for 1 h. After successive washings with TBS con- 
taining 0.05% Tween 20 and then with TBS, immunoreactive bands 
were stained by the Immun-Lite II kit (Bio-Rad). Gels were calibrated 
with the protein markers (low range SDS-polyacrylamide g ls electro- 
phoresis tandards, Bio-Rad or Rainbow colored protein molecular 
weight markers, Amersham). Protein was determined with bicincho- 
ninic acid protein assay reagent (Pierce, Rockford) and bovine serum 
albumin as a standard. 
2.4. PGI2 synthase assay 
The activity of PGI2 synthase was determined as described pre- 
viously [6]. Briefly, the reaction mixture for PGI2 synthase assay con- 
tained 0.1 M Tris-HC1 buffer, pH 7.4, [1-a4C]PGH2 (5 nmol), and an 
enzyme preparation in a final volume of 100 lal. The reaction was 
carried out at 24°C for the specified time (0-30 s) and terminated 
by the addition of 0.3 ml of diethyl ether/methanol/0.2 M citric acid 
(30:4:1). The organic phase (100 lal) was directly applied on a silica 
gel plate at 4°C, and the plate was developed at room temperature 
using an organic layer of ethyl acetate/2,2,4-trimethylpentane/acetic 
acid/water (110:50:20:100). The amounts of 14C-labeled PGH2 and 
6-keto-PGFla, a stable degradation product of PGI2, were visualized 
and calculated using an imaging analyzer (BAS2000, Fuji Photo Film 
Co.), 
3. Results and discussion 
Previously, we expressed bovine PGI~ synthase with an ex- 
pression vector pcDL-SRc~296 in COS-7 cells but the level of 
consensus  
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Fig. 1. Alignment of amino-acid sequences in the heme proximal region of PGI2 synthase and P450s. The trivial name, standard nomenclature, 
and source organism for the sequences presented are: PGI2 synthase (PGIS) (CYP8, human), P450ch7ot (CYP7, human) [26], TXS (CYP5, hu- 
man) [27], P450d (CYP1A2, rat) [28], P450M1 (CYP2C11, rat) [29], P450cam (CYP101, Pseudomonas putida) [30,31], P450trp (CYP108, Pseudo- 
monas spp.) [32], P450BM-3 (CYP102, Bacillus megaterium) [33], P450nor (CYP55, Fusarium oxysporum) [34]. The asterisks indicate Cys 44t, 
Glu 347 and Arg 35° of PGI2 synthase, which are conserved in each of these P450s. The consensus sequence is presented as follows: upper-case 
letter, 100% conservation; lower-case letter, most frequently occurring amino acid in ->85% of the sequences. The approximate location of he- 
lices K and L in the known three crystal structures of P450cam, P450terp and P450BM-3 is shown below the sequences. The standard single- 
letter code is used. 
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Fig. 2. SDS-polyacrylamide gel electrophoresis, mmunoblot analysis and determination f enzymatic activity of the mutant PGI2 synthase x- 
pressed in the microsomes from expression-vector transfected 293 cells• (A) Electrophoresis of microsomal fraction (10 gg protein) was carried 
out on 10% (w/v) SDS-polyacrylamide g l, and proteins were stained with silver nitrate. Protein size markers are indicated in kDa on the left 
side. (B) Microsomal proteins (40 gg) separated on 10% (w/v) SDS-polyacrylamide gel were transfered onto PVDF membrane, which was trea- 
ted with rabbit polyclonal anti-bovine PGI2 synthase antibody. (C) Microsomal fractions (20 gg) were incubated with 14C-labeled PGH2 (5.0 
nmol) at 24°C for 30 s. The reaction products were separated by thin-layer chromatography and radioactive products were detected using a 
BAS2000 image analyzer. Migrations of PGH2 and 6-keto-PGFlCt are indicated by bars. Lanes: 1, human wild-type PGI2 synthase; 2, Cys 441- 
Ala mutant; 3, Cys441His mutant; 4, Cysa41Ser mutant; 5, mock (pCMV-7). 
the expressed enzyme was too low to characterize the enzyme 
[6]. Thus, we first attempted to establish an efficient system for 
expressing the wild-type human PGI2 synthase with our 
cloned cDNA [7]. An expression vector (pCMV-7) with an 
insert of the entire protein-coding region of the cDNA for 
the enzyme (pCMV/PGISWT) was constructed and trans- 
fected into 293 cells. As shown in Fig. 2A, a 51 kDa protein 
was expressed in the microsomal fractions of the transfected 
cells (lane 1); this band was not found in the mock (pCMV- 
7)-transfected cells (lane 5). Furthermore, the same microso- 
mal fractions were subjected to immunoblot analysis using the 
polyclonal antibody against bovine PGI2 synthase [15]. As 
shown in Fig. 2B, a specific immunoreactive band correspond- 
ing to the 51 kDa protein was observed only with the cells 
transfected with pCMV/PGISWT (lane 1). In order to exam- 
ine the PGI2 synthase activity of the expressed protein, the 
microsomal fractions were incubated with 14C-labeled PGH~ 
as a substrate. Fig. 3 demonstrates that the substrate was 
converted to 6-keto-PGFl~, a stable degradation product of 
PGI~ (panel A, lanes 2-4). The formation of 6-keto-PGFl,~ 
was linear at least for the initial 30 s with a concomitant 
decrease of PGH2 (Fig. 3B) and the activity of the preparation 
was 96 nmol 6-keto-PGF1Jmin per mg protein. This activity 
was about 8 times as much as that of bovine aorta micro- 
somes [16]. The microsomal fractions transfected with the 
control vector without insert showed no detectable PGI2 
synthase activity (Fig. 3A, lane 5). These results indicated 
that the wild-type human PGI2 synthase could be expressed 
at a sufficient level for characterization of the enzyme using 
pCMV-7 inserted with the human PGI2 synthase cDNA in 
293 cells. 
We applied this expression system for the site-directed mu- 
tagenesis study of the human PGI2 synthase. According to the 
three-dimensional structure of P450 . . . .  the heme disc em- 
bedded between helices I and L constituting the active site. 
Such an arrangement is a common feature in many heme 
proteins [17]. As shown in Fig. 1, comparison of the amino 
acid sequence of human PGIe synthase with P450s shows that 
the PGI2 synthase has a significant sequence similarity to 
other P450s in the C-terminal region including the Cys-pocket 
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Fig. 3. Time course of isomerization of PGH~ by recombinant hu- 
man PGI2 synthase. Microsomal fractions (8.9 ktg) from cells trans- 
fected with the expression vector coding for the wild-type enzyme 
were incubated with 14C-labeled PGH2 (5.0 nmol) at 24°C for speci- 
fied times. (A) The reaction products were separated by thin-layer 
chromatography, and radioactive products were detected using a 
BAS2000 image analyzer. Migrations of PGH2 and 6-keto-PGFla 
are indicated by bars. (B) Amounts of 6-keto-PGFla nd PGH2 in 
the reaction mixture. Lanes 1~1 indicate the reaction mixtures incu- 
bated for 0, 10, 20 and 30 s, respectively. Lane 5, products formed 
by incubation for 30 s with microsome fraction of control cells 
transfected with the expression vector pCMV-7. 
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Fig. 4. SDS-polyacrylamide g l electrophoresis, mmunoblot analysis and PGI2-synthetic activity of the microsomes from expression-vector 
transfected 293 cells. (A) Microsomal proteins (10 lag) were analyzed by SDS-polyacrylamide g l electrophoresis a described in the legend to 
Fig. 2A. Protein size markers are indicated in kDa on the left. (B) Microsomal fractions (40 lag) were subjected to immunoblot analysis as de- 
scribed in Fig. 2B. (C) Determination of enzyme activities of microsomal fractions (20 I.tg) were performed as described in Fig. 2C. Lanes: 1, 
wild-type enzyme; 2, GluaaZAla; 3, Arg35°Ala; 4, mock. Migrations of PGH2 and 6-keto-PGFlct are indicated. Lanes: 1, human wild-type 
PGI~ synthase; 2, Glua4ZAla; 3, ArgZS°Ala; 4, mock (vector pCMV-7). 
near the helix L. The cysteine residue in the pocket has been 
shown to constitute the fifth ligand of the heme iron [17-21]. 
Thus, it is very possible that this invariant cysteine residue 
with a polar side chain at position 441 of the PGI2 synthase 
plays an important role in the catalytic activity of the enzyme. 
For confirmation of this possibility we substituted alanine and 
serine for Cys 441 by site-directed mutagenesis. The Cys441Ala 
and Cys441Ser mutants were expressed in 293 cells under the 
same conditions as used for the expression of the wild-type 
enzyme. Both mutant proteins were expressed at similar levels 
to that of the wild-type enzyme, as revealed by SDS-poly- 
acrylamide gel electrophoresis and immunoblot analysis 
(Fig. 2A,B, lanes 2,4), but no PGIz synthase activities could 
be detected ( < 0.2 nmol 6-keto-PGF1Jmin per mg protein) in 
the microsome fractions from the 293 cells expressing Cy- 
s441Ala or Cys441Ser (Fig. 2C, lanes 2,4). Similarly, it was 
reported that the substitution of histidine for this cysteine in 
rat P450d caused a loss of catalytic activity of the enzyme [20]. 
In contrast, Tomura et al. [22] reported that the substitution 
of histidine for this cysteine in Fusariurn oxysporum P450nor 
retained a weak but significant level of the enzymatic activity. 
In order to examine the effect of this substitution in human 
PGI2 synthase, we replaced the Cys TM by histidine. An unde- 
tectable level of the PGI2 synthase activity (< 0.2 nmol 6- 
keto-PGFla/min per mg protein) was observed with the mi- 
crosome fractions from the cells expressing Cys441His (Fig. 
2C, lane 3), although the mutant protein was expressed at a 
similar level to the wild-type (Fig. 2A,B, lane 3). These results 
suggest hat the Cys 441 of human PGI2 synthase is a critical 
residue for the catalytic activity of the enzyme as shown by 
P450d [20] and thromboxane synthase [21]. 
As shown in Fig. 1, the EXXR motif in helix K, which is 
highly invariant among sequences of P450s, is also conserved 
in that of the PGI2 synthase [8,9]. In addition, it is considered 
that the EXXR motif of P450cam located on helix K stabilizes 
the helix by forming two hydrogen bonds between the side 
chains of the Glu and Arg residues, and these hydrogen bonds 
are structurally important [23]. To assess the importance of 
these residues in the catalytic function of the PGI2 synthase, 
we changed Glu 347 or Arg 35° of the possible EXXR motif of 
the enzyme to alanine (Glu347Ala or Arg35°Ala) as shown in 
Fig. 4A,B (lanes 2,3). Low enzymatic activities of these mu- 
tants ( < 0.2 nmol 6-keto-PGFiJmin per mg protein) could be 
detected with the microsome fractions from the cells expres- 
sing Glu347Ala or Arg35°Ala (Fig. 4C, lanes 2,3). Our results 
indicate that Glu 347 and Arg 35° of human PGI2 synthase play 
a critical role in the enzyme catalysis. Similarly, Chen and 
Zhou [24] reported that mutation of Arg ~5 in helix K of 
aromatase (P450arom) led to the production of inactive pro- 
tein. Shimizu et al. [25] reported that mutants of the corre- 
sponding arginine residue of P450d were inactive, and that 
these mutants did not bind the heme in the active site of 
P450d. The results of the present study suggest that the highly 
conserved EXXR motif among P450s is essential for the ex- 
pression of the PGI2 synthase activity, although the PGI2 
synthase has a unique isomerase activity unlike many other 
cytochrome P450s. 
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